Intellia Therapeutics (NTLA) EBIT Margin Growth (3y) (2018 - 2026)

Intellia Therapeutics (NTLA) EBIT Margin Growth (3y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 9,942.00
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -1,211.00
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -623.00
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Intellia Therapeutics 1.27 Bn 1.27 Bn - 22,006.00

Historic Data

Download Data
DateValue
Mar 31, 2026 22,006.00
Dec 31, 2025 38,222.00
Sep 30, 2025 -1,337.00
Jun 30, 2025 -7,152.00
Mar 31, 2025 55,539.00
Dec 31, 2024 -43,426.00
Sep 30, 2024 -58,961.00
Jun 30, 2024 -94,491.00
Mar 31, 2024 32,633.00
Dec 31, 2023 794,034.00
Sep 30, 2023 -96,682.00
Jun 30, 2023 -77,035.00
Mar 31, 2023 -63,226.00
Dec 31, 2022 -53,884.00
Sep 30, 2022 -55,691.00
Jun 30, 2022 -45,366.00
Mar 31, 2022 -105,375.00
Dec 31, 2021 -36,233.00
Sep 30, 2021 -67,404.00
Jun 30, 2021 -74,635.00